Background: Type D personality is considered as an independent risk factor for morbidity and mortality in cardiovascular patients and a vulnerability factor for distress in the general population. Because representative community studies are rare, we sought to determine the prevalence of type D personality and its relationship with demographic characteristics, different features of mental disorders, cardiovascular risk factors, health behavior, endothelial function and cardiovascular biomarkers in the general population. Methods: The prevalence of type D personality and its correlates were analyzed cross-sectionally in a population-based sample of 5,000 Mid-Europeans aged 35–74 years from the Gutenberg Health Study. Results: The prevalence of type D personality was 22.2% without remarkable differences in sex distribution. Type D subjects were characterized by lower socioeconomic status, lack of a partnership, increased depression, anxiety, depersonalization and health care utilization. Despite its strong association with mental disorders, type D personality emerged as psychometrically distinct. Although type D personality was independently associated with coronary heart disease (OR = 1.54, p = 0.044), no associations with traditional cardiovascular risk factors were found independently from depression or anxiety. Conclusions: Although type D personality is strongly associated with depression, anxiety, impaired mental and somatic health status, and increased health care utilization, the type D construct seems to comprise dysfunctional personality patterns not covered by depression and anxiety scales. Beyond these associations, the pathways of the cardiotoxic impact of type D personality remain to be elucidated. There is a need for prospective population studies on potential links between type D personality and cardiac disease.

Keywords:
Type D personality, Depression, Anxiety, Coronary heart disease, Inflammation, Endothelial function, Lifestyle
1.
Denollet J: DS14: standard assessment of negative affectivity, social inhibition, and type D personality. Psychosom Med 2005;67:89–97.
2.
Denollet J, Schiffer AA, Spek V: A general propensity to psychological distress affects cardiovascular outcomes: evidence from research on the Type D (distressed) personality profile. Circ Cardiovasc Qual Outcomes 2010;3:546–557.
3.
Denollet J, Sys SU, Stroobant N, Rombouts H, Gillebert TC, Brutsaert DL: Personality as independent predictor of long-term mortality in patients with coronary heart disease. Lancet 1996;347:417–421.
4.
Hausteiner C, Klupsch D, Emeny R, Baumert J, Ladwig KH: Clustering of negative affectivity and social inhibition in the community: prevalence of type D personality as a cardiovascular risk marker. Psychosom Med 2010;72:163–171.
5.
Grande G, Jordan J, Kümmel M, Struwe C, Schubmann R, Schulze F, Unterberg C, von Känel R, Kudielka BM, Fischer J: Evaluation der deutschen Typ D-Skala (DS14) und Prävalenz der Typ D-Persönlichkeit bei kardiologischen und psychosomatischen Patienten sowie Gesunden. Psychother Psychosom Med Psychol 2004;54:413–422.
6.
Martens EJ, Kupper N, Pedersen SS, Aquarius AE, Denollet J: Type-D personality is a stable taxonomy in post-MI patients over an 18-month period. J Psychosom Res 2007;63:545–550.
7.
Pelle AJ, Erdman RAM, van Domburg RT, Spiering M, Kazemier M, Pedersen SS: Type D patients report poorer health status prior to and after cardiac rehabilitation compared to non-type D patients. Ann Behav Med 2008;36:167–175.
8.
Kupper N, Boomsma DI, de Geus EJ, Denollet J, Willemsen G: Nine-year stability of Type D personality: contributions of genes and environment. Psychosom Med 2011;73:75–82.
9.
Dannemann S, Matschke K, Einsle F, Smucker MR, Zimmermann K, Joraschky P, Weidner K, Kollner V: Is type-D a stable construct? An examination of type-D personality in patients before and after cardiac surgery. J Psychosom Res 2010;69:101–109.
10.
Denollet J, Vaes J, Brutsaert DL: Inadequate response to treatment in coronary heart disease: adverse effects of type D personality and younger age on 5-year prognosis and quality of life. Circulation 2000;102:630–635.
11.
Martens EJ, Mols F, Burg MM, Denollet J: Type D personality predicts clinical events after myocardial infarction, above and beyond disease severity and depression. J Clin Psychiatry 2010;71:778–783.
12.
Reich J, Schatzberg A: Personality traits and medical outcome of cardiac illness. J Psychiatr Res 2010;44:1017–1020.
13.
Schiffer AA, Pedersen SS, Widdershoven JW, Denollet J: Type D personality and depressive symptoms are independent predictors of impaired health status in chronic heart failure. Eur J Heart Fail 2008;10:922–930.
14.
Schiffer AA, Pedersen SS, Broers H, Widdershoven JW, Denollet J: Type-D personality but not depression predicts severity of anxiety in heart failure patients at 1-year follow-up. J Affect Disord 2008;106:73–81.
15.
Schiffer AA, Smith OR, Pedersen SS, Widdershoven JW, Denollet J: Type D personality and cardiac mortality in patients with chronic heart failure. Int J Cardiol 2010;142:230–235.
16.
Schiffer AA, Pedersen SS, Widdershoven JW, Hendriks EH, Winter JB, Denollet J: The distressed (Type D) personality is independently associated with impaired health status and increased depressive symptoms in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2005;12:341–346.
17.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
18.
Lowe B, Spitzer RL, Grafe K, Kroenke K, Quenter A, Zipfel S, Buchholz C, Witte S, Herzog W: Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord 2004;78:131–140.
19.
Michal M, Wiltink J, Till Y, Wild PS, Munzel T, Blankenberg S, Beutel ME: Type-D personality and depersonalization are associated with suicidal ideation in the German general population aged 35–74: results from the Gutenberg Heart Study. J Affect Disord 2010;125:227–233.
20.
Martens EJ, Smith OR, Winter J, Denollet J, Pedersen SS: Cardiac history, prior depression and personality predict course of depressive symptoms after myocardial infarction. Psychol Med 2008;38:257–264.
21.
Pedersen SS, van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM: Type D personality is associated with increased anxiety and depressive symptoms in patients with an implantable cardioverter defibrillator and their partners. Psychosom Med 2004;66:714–719.
22.
Pelle AJ, Denollet J, Zwisler AD, Pedersen SS: Overlap and distinctiveness of psychological risk factors in patients with ischemic heart disease and chronic heart failure: are we there yet? J Affect Disord 2009;113:150–156.
23.
Spindler H, Kruse C, Zwisler AD, Pedersen SS: Increased anxiety and depression in Danish cardiac patients with a type D personality: cross-validation of the Type D Scale (DS14). Int J Behav Med 2009;16:98–107.
24.
Schiffer AA, Denollet J, Widdershoven JW, Hendriks EH, Smith OR: Failure to consult for symptoms of heart failure in patients with a type-D personality. Heart 2007;93:814–818.
25.
Pelle AJ, Schiffer AA, Smith OR, Widdershoven JW, Denollet J: Inadequate consultation behavior modulates the relationship between type D personality and impaired health status in chronic heart failure. Int J Cardiol 2010;142:65–71.
26.
Whitehead DL, Perkins-Porras L, Strike PC, Magid K, Steptoe A: Cortisol awakening response is elevated in acute coronary syndrome patients with type-D personality. J Psychosom Res 2007;62:419–425.
27.
Molloy GJ, Perkins-Porras L, Strike PC, Steptoe A: Type-D personality and cortisol in survivors of acute coronary syndrome. Psychosom Med 2008;70:863–868
28.
Kupper N, Gidron Y, Winter J, Denollet J: Association between type D personality, depression, and oxidative stress in patients with chronic heart failure. Psychosom Med 2009;71:973–980.
29.
Denollet J, Schiffer AA, Kwaijtaal M, Hooijkaas H, Hendriks EH, Widdershoven JW, Kupper N: Usefulness of Type D personality and kidney dysfunction as predictors of interpatient variability in inflammatory activation in chronic heart failure. Am J Cardiol 2009;103:399–404.
30.
Skapinakis P: The 2-item Generalized Anxiety Disorder scale had high sensitivity and specificity for detecting GAD in primary care. Evid Based Med 2007;12:149.
31.
Connor KM, Kobak KA, Churchill LE, Katzelnick D, Davidson JR: Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety 2001;14:137–140.
32.
Löwe B, Gräfe K, Zipfel S, Spitzer RL, Herrmann-Lingen C, Witte S, Herzog W: Detecting panic disorder in medical and psychosomatic outpatients: comparative validation of the hospital anxiety and depression scale, the patient health questionnaire, a screening question, and physicians’ diagnosis. J Psychosom Res 2003;55:515–519.
33.
Michal M, Zwerenz R, Tschan R, Edinger J, Lichy M, Knebel A, Tuin I, Beutel M: Screening for depersonalization-derealization with two items of the Cambridge Depersonalization Scale. Psychother Psychosom Med Psychol 2010;60:175–179.
34.
Michal M, Wiltink J, Subic-Wrana C, Zwerenz R, Tuin I, Lichy M, Brahler E, Beutel ME: Prevalence, correlates, and predictors of depersonalization experiences in the German general population. J Nerv Ment Dis 2009;197:499–506.
35.
Kelly DH, Walter CJ: The relationship between clinical diagnosis and anxiety, assessed by forearm blood flow and other measurements. Br J Psychiatry 1968;114:611–626.
36.
Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D: Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003;56:1163–1169.
37.
Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, Paffenbarger RS Jr: Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.
38.
Lampert T, Kroll LE: Die Messung des sozioökonomischen Status in sozialepidemiologischen Studien; in Richter M, Hurrelmann K (eds): Gesundheitliche Ungleichheit. Wiesbaden, VS Verlag für Sozialwissenschaften, 2009, pp 309–334.
39.
Broek KC, Smolderen KG, Pedersen SS, Denollet J: Type D personality mediates the relationship between remembered parenting and perceived health. Psychosomatics 2010;51:216–224.
40.
Mols F, Denollet J: Type D personality among noncardiovascular patient populations: a systematic review. Gen Hosp Psychiatry 2010;32:66–72.
41.
Mols F, Denollet J: Type D personality in the general population: a systematic review of health status, mechanisms of disease, and work-related problems. Health Qual Life Outcomes 2010;8:9.
42.
Yu DS, Thompson DR, Yu CM, Pedersen SS, Denollet J: Validating the type D personality construct in Chinese patients with coronary heart disease. J Psychosom Res 2010;69:111–118.
43.
Pietrzak RH, Wagner JA, Petry NM: DSM-IV personality disorders and coronary heart disease in older adults: results from the national epidemiologic survey on alcohol and related conditions. J Gerontol B Psychol Sci Soc Sci 2007;62:295–299.
44.
Michal M, Wiltink J, Till Y, Wild PS, Blettner M, Beutel ME: Distinctiveness and overlap of depersonalization with anxiety and depression in a community sample: results from the Gutenberg Heart Study. Psychiatry Res 2011;188:264–268.
45.
Pizzi C, Manzoli L, Mancini S, Costa GM: Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2008;29:1110–1117.
46.
Ali S, Garg SK, Cohen BE, Bhave P, Harris WS, Whooley MA: Association between omega-3 fatty acids and depressive symptoms among patients with established coronary artery disease: data from the heart and soul study. Psychother Psychosom 2009;78:125–127.
47.
Rapp MA, Rieckmann N, Lessman DA, Tang CY, Paulino R, Burg MM, Davidson KW: Persistent depressive symptoms after acute coronary syndrome are associated with compromised white matter integrity in the anterior cingulate: a pilot study. Psychother Psychosom 2010;79:149–155.
48.
Yoon SJ, Kim TS, Seung KB, Kim PJ, Lee C, Jun TY, Lee CU, Lyoo IK: Role of depressive symptoms in coronary artery spasm. Psychother Psychosom 2009;79:191–193.
49.
Bui E, Cailhol L, Puel J, Birmes P, Schmitt L: Effects of depressive symptoms, anxiety and alexithymia on physical functioning 6 months after percutaneous transluminal coronary angioplasty. Psychother Psychosom 2009;79:59–60.
50.
Zuidersma M, Thombs BD, de Jonge P: Onset and recurrence of depression as predictors of cardiovascular prognosis in depressed acute coronary syndrome patients: a systematic review. Psychother Psychosom 2011;80:227–237.
51.
Bankier B, Barajas J, Martinez-Rumayor A, Januzzi JL: Association between major depressive disorder and C-reactive protein levels in stable coronary heart disease patients. J Psychosom Res 2009;66:189–194.
52.
Känel RV, Bellingrath S, Kudielka BM: Association between longitudinal changes in depressive symptoms and plasma fibrinogen levels in school teachers. Psychophysiology 2009;46:473–480.
53.
Panagiotakos DB, Pitsavos C, Chrysohoou C, Tsetsekou E, Papageorgiou C, Christodoulou G, Stefanadis C: Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the Attica Study. Eur Heart J 2004;25:492–499.
54.
Politi P, Minoretti P, Piaggi N, Brondino N, Emanuele E: Elevated plasma N-terminal ProBNP levels in unmedicated patients with major depressive disorder. Neurosci Lett 2007;417:322–325.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.